131 related articles for article (PubMed ID: 24092864)
1. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
Pécheur EI
Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
[No Abstract] [Full Text] [Related]
2. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
[TBL] [Abstract][Full Text] [Related]
3. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
6. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
7. Gumming up the works: DNA polymers as HCV entry inhibitors.
Counihan NA; Lindenbach BD
Gastroenterology; 2009 Aug; 137(2):427-30. PubMed ID: 19563837
[No Abstract] [Full Text] [Related]
8. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
9. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process.
Lv XQ; Zou LL; Tan JL; Li H; Li JR; Liu NN; Dong B; Song DQ; Peng ZG
Eur J Pharmacol; 2020 Sep; 883():173323. PubMed ID: 32622669
[TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro.
Hang X; Peng H; Song H; Qi Z; Miao X; Xu W
J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793
[TBL] [Abstract][Full Text] [Related]
12. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
[TBL] [Abstract][Full Text] [Related]
13. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Xiao F; Fofana I; Thumann C; Mailly L; Alles R; Robinet E; Meyer N; Schaeffer M; Habersetzer F; Doffoël M; Leyssen P; Neyts J; Zeisel MB; Baumert TF
Gut; 2015 Mar; 64(3):483-94. PubMed ID: 24848265
[TBL] [Abstract][Full Text] [Related]
14. Selection of peptides binding to HCV e2 and inhibiting viral infectivity.
Hong HW; Lee SW; Myung H
J Microbiol Biotechnol; 2010 Dec; 20(12):1769-71. PubMed ID: 21193836
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
16. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
Pawlotsky JM
Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973
[No Abstract] [Full Text] [Related]
17. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.
Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T
Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774
[TBL] [Abstract][Full Text] [Related]
18. New targets for treatment against HCV infection.
Pan Q; van der Laan LJ
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):505-15. PubMed ID: 23199508
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
20. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Descamps V; Helle F; Louandre C; Martin E; Brochot E; Izquierdo L; Fournier C; Hoffmann TW; Castelain S; Duverlie G; Galmiche A; François C
Antiviral Res; 2015 Jun; 118():93-102. PubMed ID: 25823619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
